Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review

被引:20
作者
Giannelos, Nikolaos [1 ,3 ]
Ng, Cheryl [2 ]
Curran, Desmond [1 ]
机构
[1] GSK, Value Evidence, Wavre, Belgium
[2] GSK, Value Evidence, Singapore, Singapore
[3] GSK, Vaccines R&D, Ave Fleming 20, B-1300 Wavre, Belgium
关键词
Herpes zoster; vaccination; recombinant zoster vaccine; cost-effectiveness; older adults; NET MONETARY BENEFIT; POSTHERPETIC NEURALGIA; SUBUNIT VACCINE; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; TERM PERSISTENCE; UNITED-STATES; EFFICACY; ADULTS; RECOMMENDATIONS;
D O I
10.1080/21645515.2023.2168952
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The objective of this study was to critically review the cost-effectiveness (CE) of the recombinant zoster vaccine (RZV) against herpes zoster (HZ). A literature review was conducted in PubMed, Embase, and Cochrane between January 1, 2017, and February 28, 2022, and on select public healthcare agency websites to identify and collect data from CE studies comparing RZV to zoster vaccine live (ZVL) or to no vaccination. Study characteristics, inputs, and outputs were collected. The overall CE of RZV was assessed. RZV vaccination against HZ is cost-effective in 15 out of 18 studies included in the present review. Varying incremental cost-effectiveness ratios (ICERs) observed may be associated with different assumptions on the duration of protection of RZV, as well as different combinations of structural and disease-related study (model) inputs driving the estimation of ICERs. Plain Language SummaryWhat is the context?center dot Herpes zoster, also known as shingles, may cause painful rashes and skin alterations.center dot Chronic pain, also referred to as post-herpetic neuralgia, may persist for months or even years after the initial rash.center dot The disease is caused by reactivation of the varicella zoster virus.center dot The recombinant zoster vaccine (RZV) and the zoster vaccine live (ZVL) are approved for the prevention of herpes zoster and post-herpetic neuralgia.center dot We reviewed published evidence from the past 5 years on RZV.What is new?center dot Out of 18 selected studies, RZV vaccination against herpes zoster and post-herpetic neuralgia is cost-effective in 15.center dot In the 15 studies establishing RZV cost-effectiveness, RZV is always cost-effective or frequently cost-saving in direct comparisons to ZVL, when applicable.center dot RZV was found cost-saving in several immune-compromised populations.What is the impact?center dot The overview of the currently available body of evidence related to cost-effectiveness of RZV may help informing decision makers about the value of vaccination against herpes zoster.
引用
收藏
页数:13
相关论文
共 50 条
[41]   Modelling the Public Health Burden of Herpes Zoster and the Impact of Adjuvanted Recombinant Zoster Vaccine in Five Selected Countries in Southeast Asia [J].
Han, Ru ;
San Martin, Peter ;
Ahmed, Nurilign ;
Guzman-Holst, Adriana ;
Mohy, Ahmed ;
Pinto, Thatiana ;
de Veras, Bruna ;
Gomez, Jorge A. ;
Bibera, Gyneth Lourdes ;
van Oorschot, Desiree A. M. .
INFECTIOUS DISEASES AND THERAPY, 2024, 13 (04) :761-778
[42]   Primary care physicians' experience with zoster vaccine live (ZVL) and awareness and attitudes regarding the new recombinant zoster vaccine (RZV) [J].
Hurley, Laura P. ;
Allison, Mandy A. ;
Dooling, Kathleen L. ;
O'Leary, Sean T. ;
Crane, Lori A. ;
Brtnikova, Michaela ;
Beaty, Brenda L. ;
Allen, Jessica A. ;
Guo, Angela ;
Lindley, Megan C. ;
Kempe, Allison .
VACCINE, 2018, 36 (48) :7408-7414
[43]   Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines [J].
de Boer, Pieter T. ;
van Lier, Alies ;
de Melker, Hester ;
van Wijck, Albert J. M. ;
Wilschut, Jan C. ;
van Hoek, Albert Jan ;
Postma, Maarten J. .
BMC MEDICINE, 2018, 16
[44]   Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer [J].
Curran, Desmond ;
Patterson, Brandon J. J. ;
Carrico, Justin ;
Salem, Ahmed ;
La, Elizabeth M. M. ;
Lorenc, Stephane ;
Hicks, Katherine A. A. ;
Poston, Sara ;
Carpenter, Christopher F. F. .
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (01)
[45]   Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complications [J].
Strezova, Ana ;
Domingo, Javier Diez ;
Cunningham, Anthony L. ;
Eto, Takashi ;
Andrews, Charles ;
Arns, Clovis ;
Choo, Eun-Ju ;
Hui, David Shu Cheong ;
Icardi, Giancarlo ;
Mcneil, Shelly A. ;
Poder, Airi ;
Kosina, Pavel ;
Rombo, Lars ;
Schwarz, Tino F. ;
Tinoco, Juan Carlos ;
Yu, Chong-Jen ;
Wang, Jing ;
Soni, Jyoti ;
Tsang, Manyee ;
Leon, Rafael ;
Mwakingwe-Omari, Agnes .
ECLINICALMEDICINE, 2025, 83
[46]   Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults [J].
McGirr, Ashleigh ;
Van Oorschot, Desiree ;
Widenmaier, Robyn ;
Stokes, Michael ;
Ganz, Michael L. ;
Jung, Hyosung ;
Varghese, Lijoy ;
Curran, Desmond .
APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2019, 17 (05) :723-732
[47]   Systematic review and meta-analysis of recombinant herpes zoster vaccine in immunocompromised populations [J].
Marra, Fawziah ;
Yip, Michael ;
Cragg, Jacquelyn J. ;
Vadlamudi, Nirma Khatri .
PLOS ONE, 2024, 19 (11)
[48]   Herpes zoster vaccine effectiveness against herpes zoster and postherpetic neuralgia in New Zealand: a retrospective cohort study [J].
Mbinta, James F. ;
Wang, Alex X. ;
Nguyen, Binh P. ;
Paynter, Janine ;
Awuni, Prosper Mandela A. ;
Pine, Russell ;
Sporle, Andrew A. ;
Simpson, Colin R. .
LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2023, 31
[49]   Cost Effectiveness of Herpes Zoster Vaccine in Canada [J].
Najafzadeh, Mehdi ;
Marra, Carlo A. ;
Galanis, Eleni ;
Patrick, David M. .
PHARMACOECONOMICS, 2009, 27 (12) :991-1004
[50]   Cost Effectiveness of Herpes Zoster Vaccine in Canada [J].
Mehdi Najafzadeh ;
Carlo A. Marra ;
Eleni Galanis ;
David M. Patrick .
PharmacoEconomics, 2009, 27 :991-1004